文献速递心境障碍

辅助经颅交流电刺激治疗双相抑郁的随机对照试验

Efficacy and safety of adjunctive transcranial alternating current stimulation in bipolar depression: A randomized controlled trial.
PubMed 文献 · Mol Psychiatry · 2026-07-22

活性tACS组第2周应答率显著高于假刺激组(46.7% vs 20.0%),第4周亦更高(70.0% vs 43.3%),并伴焦虑、睡眠和躁狂症状改善,耐受性相当。

要点

  • 辅助10 Hz tACS两周可提高双相抑郁第2周和第4周抗抑郁应答率。
  • 活性tACS组焦虑和睡眠症状改善更明显,躁狂症状更少,认知无差异。
  • 最常见不良事件为头痛和头晕,两组耐受性相当。

核心结论

  • 辅助tACS与双相抑郁早期抑郁、焦虑和睡眠症状更大改善相关,总体安全且耐受良好。
  • 鉴于方法学局限,结果应视为假设生成性,需未来研究证实。

研究设计与样本

  • 每日两次、共两周,同时服用锂盐500 mg/日,每次2 mA、20分钟、双侧背外侧前额叶,间隔70分钟,共20次。
  • 治疗后随访6周,主要终点为第2周抗抑郁应答(HAMD-17评分下降≥50%)。

主要发现

  • 活性tACS组第2周应答率为46.7%,假刺激组为20.0%。
  • 活性tACS组第4周应答率为70.0%,假刺激组为43.3%。
  • 活性tACS组焦虑和睡眠症状改善更明显,躁狂症状更少,认知结局无差异。
  • 最常见治疗相关不良事件为头痛和头晕,两组耐受性相当。
  • 两周干预后静息态EEG显示假刺激组额叶和顶叶delta功率显著增加,活性tACS组无此变化;假刺激组顶叶delta功率增加与HAMD-17减分负相关。

关键数值与推荐

  • 主要终点第2周应答定义为HAMD-17评分较基线下降≥50%。
  • 活性tACS参数为10 Hz、2 mA、20分钟、双侧背外侧前额叶,每日两次,共20次。
  • 辅助用药为锂盐500 mg/日。

临床怎么用

  • 对于双相抑郁患者,可在锂盐基础上考虑辅助10 Hz tACS以争取早期抑郁、焦虑和睡眠症状改善。
  • 治疗期间需关注头痛和头晕等常见不良事件,并监测躁狂症状。
  • 当前证据为初步性,临床决策应结合个体情况并等待进一步验证。

局限性

  • 研究为初步证据,存在方法学局限,结果需视为假设生成性。
  • 未来需改进假刺激程序、采用无锂盐设计和更长随访以确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bipolar depression represents a significant public health challenge, with limited efficacy and tolerability of available pharmacotherapies, driving interest in novel treatment approaches. Transcranial alternating current stimulation (tACS), a noninvasive brain stimulation technique capable of modulating neural oscillations, has not yet been clearly established as an effective treatment for bipolar depression. In this randomized, double-blind, sham-controlled trial, we evaluated the efficacy, safety, and electroencephalography (EEG) effects of adjunctive tACS in individuals with bipolar depression. Sixty participants were randomized to receive either active 10-Hz tACS or sham stimulation twice daily for two weeks, alongside lithium (500 mg/day). Each session delivered 2 mA current for 20 min bilaterally over the dorsolateral prefrontal cortices, with a 70-minute interval between sessions, totaling 20 sessions. Participants were followed for 6 weeks after treatment. The primary endpoint was antidepressant response at week 2, defined as a >=50% reduction in the 17-item Hamilton Depression Rating Scale (HAMD-17) score. Secondary outcomes included changes in anxiety, sleep, mania, cognition, and EEG. Compared with sham, active tACS showed significantly higher response rates at week 2 (46.7 vs. 20.0%) and week 4 (70.0 vs. 43.3%). Active tACS also showed greater reductions in anxiety and sleep symptoms and fewer manic symptoms, with no differences in cognitive outcomes. The most common treatment-related adverse events were headache and dizziness, with tolerability being comparable between the groups. Resting-state EEG assessments following the 2-week intervention revealed that, in the sham group receiving lithium alone, delta power significantly increased in the frontal and parietal regions, while no such changes were observed in the active tACS group. Moreover, increased parietal delta power was negatively correlated with HAMD-17 reduction in the sham group. This study provides preliminary evidence that adjunctive tACS was associated with greater early improvement in depressive, anxiety, and sleep symptoms, with a generally safe and well tolerated profile. Given the remaining methodological limitations, these findings should be considered hypothesis-generating and require confirmation in future studies with improved sham procedures, lithium-free designs, and longer follow-up.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Xu J, Li D, Liu Y, et al. Efficacy and safety of adjunctive transcranial alternating current stimulation in bipolar depression: A randomized controlled trial. Mol Psychiatry. 2026. PMID: 42486942. doi:10.1038/s41380-026-03778-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。